Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2024 07:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...
September 30, 2024 07:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
January 30, 2023 09:15 ET | Source: Aesther Healthcare Acquisition Corp.

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers

Results outline novel bispecific antibody approach that generates strong anti-tumor response in malignant melanoma, holding potential to control important pathways in multiple cancer types Ocean...
October 20, 2022 09:22 ET | Source: The Insight Partners

T-Cell Therapy Market Size to Hit $21+ Billion with Booming CAGR Value of 20.7% by 2028 | The Insight Partners

New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "T-cell Therapy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and...
August 15, 2022 13:50 ET | Source: Straits Research

Next-Generation Gynecological Cancer Diagnostics Market Size is projected to reach USD 5.45 Billion by 2030, growing at a CAGR of 10.68%: Straits Research

New York, United States, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Uterine, ovarian, and cervical cervix cancers are the most common in women. Cervical cancer ranks fourth among women's...
June 15, 2022 07:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention

AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
May 20, 2022 09:15 ET | Source: Qualigen Therapeutics, Inc.

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
August 19, 2021 09:27 ET | Source: Vyant Bio, Inc.

Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
July 28, 2021 08:30 ET | Source: Tryp Therapeutics Inc.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
December 01, 2020 09:30 ET | Source: Vivos Inc.

Vivos Inc Extends it Intellectual Property Protection

Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...

Next Page keyboard_arrow_right